This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Immunization  • HIV/AIDS  • Randomized Controlled Trial  • Adverse Effects  • Alert me on articles by topic

Joan Stephenson, PhD

JAMA. 2007;298(23):2733.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

An experimental HIV vaccine used in an international trial may have increased the risk of HIV infection among vaccine recipients, according to reports in November at a special open meeting of the HIV Vaccine Trials Network in Seattle (http://www.hvtn.org). The phase 2 trial, which involved 3000 volunteers at high risk for HIV infection, was halted in late September after a preliminary analysis revealed the vaccine had failed to show efficacy.

The vaccine used a replication-defective version of a common cold virus, adenovirus type 5, as a delivery vector for 3 synthetically produced HIV genes.

A vaccine targeting HIV that was used in a recent trial may have increased the risk of HIV infection among vaccine recipients. (Photo credit: C. Goldsmith/CDC)

The increased risk was mostly seen in vaccine recipients who had high preexisting levels of immunity to adenovirus type 5. In the vaccinated group, 21 . . . [Full Text of this Article]